Accessibility Menu
NeuroSense Therapeutics logo

NeuroSense Therapeutics(NASDAQ) NRSNW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-93%
5 YearN/A
1 Year-88%
1 Month-30%
$0.07
+0.00%
+0.00Today
NeuroSense Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.072026-08-31
NeuroSense Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+78.57%USD 0.042026-08-24
1 month-29.58%USD 0.102026-07-31
3 month-46.89%USD 0.132026-06-02
Year to date-78.1%USD 0.322025-12-31
1 year-87.72%USD 0.572025-08-29
3 year-62.87%USD 0.192023-09-01
Since inception-93.07%USD 1.012021-12-09

NeuroSense Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$11.13M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.61 (Low)

Price

$0.07

Volume

7

Open

$0.07

Previous Close

$0.07

Daily Range

$0.04 - $0.07

52-Week Range

$0.04 - $0.70

Estimated Earnings Date

Sep 2, 2026

NRSNW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm focused on developing innovative therapies for severe neurodegenerative diseases. The company’s lead investigational asset, PrimeC, targets amyotrophic lateral sclerosis (ALS), while its preclinical pipeline includes StabiliC for Parkinson's disease and CogniC for Alzheimer's disease.

Products and Services
  • PrimeC: An oral compound for treating ALS
  • StabiliC: A preclinical therapy aimed at Parkinson's disease
  • CogniC: A preclinical therapy targeting Alzheimer's disease
Growth Outlook
  • Strong focus on neurodegenerative diseases with significant unmet needs
  • Advancements in PrimeC's clinical trials may enhance market position
  • Potential for partnerships to accelerate development and commercialization
Financial Highlights
  • Recent quarterly net income of -$3.2 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of $166,000 as of the latest quarter
  • Operating expenses of $3.2 million in Q4 2025, indicating robust R&D commitment
NeuroSense Therapeutics is positioned in a critical sector of biotechnology, focusing on therapies that address significant health challenges. The company’s commitment to research and development is evident in its financials, with substantial investments aimed at advancing its lead product and pipeline candidates. The potential for partnerships and advancements in clinical trials could further enhance its market presence, making it a noteworthy entity in the biotechnology landscape.
AI Generated • Aug 14, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Herzliya, TA 4672562, IL

NRSNW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

1070.23%

Return on Capital

N/A

Return on Assets

-1082.20%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

7

Avg. Volume

1.36K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$11.09M

EBITDA

-$11.07M

Operating Cash Flow

-$3.67M

Capital Expenditure

-$3.00K

Free Cash Flow

-$3.68M

Cash & ST Invst.

$166.00K

Total Debt

$170.00K

NeuroSense Therapeutics Performance Analysis

NeuroSense Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
NeuroSense Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-11.4%
Q22025-06-30N/A
Q32025-09-30-40.2%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

16

N/A

Net Income

-$3.21M

-78.1%

EBITDA

-$3.19M

-80.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$166.00K

-95.1%

Total Debt

$170.00K

+132.9%

Accounts Receivable

$33.00K

-79.9%

Inventory

$0.00

N/A

Long Term Debt

$72.00K

N/A

Short Term Debt

$98.00K

+34.2%

Return on Assets

-10.82%

N/A

Return on Invested Capital

7.45%

N/A

Free Cash Flow

-$1.84M

N/A

Operating Cash Flow

-$1.84M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCLIBrainstorm Cell Therapeutics Inc.
$1.07-4.46%
ADILAdial Pharmaceuticals, Inc.
$5.75+2.68%
HCWBHCW Biologics Inc.
$3.59+4.66%
CDIOCardio Diagnostics Holdings, Inc.
$1.87+1.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About NRSNW

What is the current price of NeuroSense Therapeutics?

NeuroSense Therapeutics is trading at $0.07 per share.

What is the 52-week range for NeuroSense Therapeutics?

Over the past 52 weeks, NeuroSense Therapeutics has traded between $0.04 and $0.70.

How much debt does NeuroSense Therapeutics have?

NeuroSense Therapeutics total debt is unavailable.

How much cash does NeuroSense Therapeutics have on hand?

NeuroSense Therapeutics does not have cash on hand data available.

What is NeuroSense Therapeutics’s dividend yield?

NeuroSense Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services